[1] Zhang L, Zhao S. Severe liver injury affects the outcomes and length of hospital stay in children with community-acquired pneumonia[J]. Afr Health Sci, 2022, 22(3):578-589. [2] Lai R, Li X, Zhang J, et al. Drug-induced liver injury in children: a nationwide cohort study from China[J]. JHEP Rep, 2024, 6(8):101102. [3] Agrwal S, Kumari S, Pandey P, et al. Acute liver injury in hospitalized children: clinical and etiological profile from a tropical country[J]. J Trop Pediatr, 2026, 72(1):fmag001. [4] Mann J P, Lenz D, Stamataki Z, et al. Common mechanisms in pediatric acute liver failure[J]. Trends Mol Med, 2023, 29(3):228-240. [5] Wu Y, Dong X, Wu R, et al. Efficacy and safety of spleen aminopeptide oral lyophilized powder in ameliorating liver injury in infants and children with human cytomegalovirus infection: a single-center study in China[J]. Transl Pediatr, 2021, 10(1):136-145. [6] Mao S, Wu L, Shi W. Risk prediction for liver injury in Epstein-Barr virus infection in pediatric respiratory tract infections[J]. Ital J Pediatr, 2023, 49(1):138. [7] Tang S, Qin R, Zhang D, et al. Liver injury and prolonged hospitalization as indicators of severity in patients with adenovirus infections[J]. BMC Infect Dis, 2024, 24(1):430. [8] Influenza-Associated Acute Necrotizing Encephalopathy (IA-ANE) Working Group, Silverman A, Walsh R, et al. Influenza-associated acute necrotizing encephalopathy in US children[J]. JAMA, 2025, 334(8):692-701. [9] Eder M, Omic H, Gorges J, et al. Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease[J]. PLoS One, 2021, 16(4):e0249785. [10] Kashiwagi T, Okada Y, Nomoto K. Palivizumab prophylaxis against respiratory syncytial virus infection in children with immunocompromised conditions or down syndrome: a multicenter, post-marketing surveillance in Japan[J]. Paediatr Drugs, 2018, 20(1):97-104. [11] Martin E, Winter S, Garcin C, et al. Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency[J]. Nature, 2024, 628(8008):620-629. [12] Beer S, Wange L E, Zhang X, et al. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells[J]. Proc Natl Acad Sci U S A, 2022, 119(30):e2200512119. [13] Kim J S, Hur D Y. Pan-aurora kinase inhibitor danusertib induces apoptosis of Epstein-Barr virus-transformed B-cells through caspase and endoplasmic reticulum stress signaling[J]. Anticancer Res, 2022, 42(11):5265-5274. [14] Tanriverdi E S, Yakupogullari Y, Bayindir Y, et al. Predictive value of pretransplant cytomegalovirus-specific cellular immunity for posttransplant CMV infection in liver transplant recipients under antiviral prophylaxis[J]. Transplant Proc, 2025, 57(8):1603-1609. [15] Kleiboeker H L, Descourouez J L, Saddler C M, et al. De novo letermovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients[J]. Clin Transplant, 2025, 39(5):e70169. [16] Zheng Y, He D, Zuo W, et al. Influenza A virus dissemination and infection leads to tissue resident cell injury and dysfunction in viral sepsis[J]. EBioMedicine, 2025, 116:105738. [17] Zhang S, Hu B, Xu J, et al. Influenza A virus infection induces liver injury in mice[J]. Microb Pathog, 2019, 137:103736. |